Kalaris Therapeutics (KLRS) Common Equity (2019 - 2020)
Kalaris Therapeutics (KLRS) has 2 years of Common Equity data on record, last reported at $373.9 million in Q3 2020.
- For Q3 2020, Common Equity rose 962.56% year-over-year to $373.9 million; the TTM value through Sep 2020 reached $373.9 million, up 962.56%, while the annual FY2019 figure was -$51.5 million, N/A changed from the prior year.
- Common Equity reached $373.9 million in Q3 2020 per KLRS's latest filing, up from -$71.3 million in the prior quarter.
- Across five years, Common Equity topped out at $373.9 million in Q3 2020 and bottomed at -$71.3 million in Q2 2020.